Related by context. All words. (Click for frequent words.) 70 orally bioavailable 68 liposomal formulation 67 CCR5 antagonist 67 MEK inhibitor 67 Pafuramidine 67 histone deacetylase HDAC inhibitor 67 sodium glucose cotransporter 67 polymerase inhibitor 67 HCV protease inhibitor 67 somatostatin analogue 66 PDE4 inhibitor 66 metaglidasen 66 INT# [002] 66 anticancer compound 66 rNAPc2 66 oral prodrug 66 TH# [003] 66 RhuDex ® 66 Maribavir 66 JAK inhibitor 65 Sym# 65 proteasome inhibitor 65 vascular disrupting agent 65 receptor tyrosine kinase inhibitor 65 non nucleoside inhibitor 65 generation purine nucleoside 65 TG# [003] 65 Xanafide 65 Ganciclovir 65 CEQ# 65 intranasal formulation 65 MB# [004] 65 anticancer agent 65 histone deacetylase inhibitor 65 Dapagliflozin 65 PN# [001] 65 PI3K inhibitor 65 humanized monoclonal antibody 65 nucleoside analog 65 TRO# 65 thymalfasin 65 Mipomersen 65 virus HCV protease inhibitor 65 TRC# 65 R#/MEM # 65 volociximab 65 targeted radiotherapeutic 65 investigational humanized monoclonal antibody 64 Civacir 64 CCR5 inhibitor 64 2 methoxyestradiol 64 mTOR inhibitor 64 HQK 64 GV# [001] 64 Phase 2b clinical trials 64 mertansine 64 investigational pan BCR 64 IMA# 64 Guanilib 64 Archexin 64 CCX# 64 proteasome inhibitors 64 renin inhibitor 64 Annamycin 64 selective orally bioavailable 64 orally administered inhibitor 64 preclinical efficacy 64 Phase Ib clinical 64 PS# [001] 64 amifampridine phosphate 64 BAL# [002] 64 systemically administered 64 immunotherapeutic agent 64 phase IIa clinical 64 Safinamide 64 Phase Ib study 64 docetaxel Taxotere R 64 Factor VIIa 64 selectively binds 64 RP# [002] 64 MEK inhibitors 64 protein kinase inhibitor 64 ALN TTR 63 TLK# 63 evaluating tivozanib 63 selective kinase inhibitor 63 TRX# 63 nanopharmaceutical 63 PD LID 63 therapeutic monoclonal antibody 63 PRT# 63 nucleoside 63 Iluvien ® 63 PSN# [002] 63 HIV integrase inhibitor 63 AEG# 63 phase IIb clinical 63 PF # [001] 63 SARMs 63 HGS# 63 TG# [001] 63 Clevudine 63 Pimavanserin 63 pan HDAC inhibitor 63 MT# MEDI 63 PEG SN# 63 selective androgen receptor modulator 63 ENMD # 63 Amrubicin 63 DG# [003] 63 ZX# [001] 63 octreotide acetate 63 dasatinib Sprycel ® 63 antisense drug 63 EOquin 63 Tyrima 63 Panzem R NCD 63 Fodosine 63 PEGylated interferon 63 HuMax CD4 63 Azedra 63 GW# [003] 63 selective adenosine 63 ganetespib 63 orally dosed 63 Aliskiren 63 Phase IIa trials 63 Darusentan 63 Nitazoxanide 63 ATL# [002] 63 OncoVEX GM CSF 63 integrase inhibitor 63 solithromycin 62 Daclizumab 62 alvespimycin 62 Multimeric 62 FOLOTYN ® 62 XL# [003] 62 Darunavir 62 generation antisense 62 HuMax EGFr 62 JAK2 inhibitor 62 radiation sensitizer 62 Elagolix 62 Raltegravir 62 XL# XL# 62 Cetuximab Erbitux 62 molecular imaging radiopharmaceutical 62 SAR# [002] 62 generation antisense inhibitor 62 Pradefovir 62 MAGE A3 ASCI 62 fosbretabulin 62 KNS # 62 ISIS # 62 ALN TTR# 62 Xyfid TM 62 TMC# [002] 62 RAV# 62 Phase #b/#a trial 62 reslizumab 62 Dasatinib 62 small molecule glucokinase 62 Proxinium TM 62 depsipeptide 62 huC# DM4 62 Irinotecan 62 selective antagonist 62 angiogenesis inhibitor 62 Preclinical studies suggest 62 anti angiogenic agent 62 Phase 2b study 62 nucleoside reverse transcriptase inhibitor 62 targeted antifolate 62 BAY #-# 62 HSP# inhibitor 62 WX UK1 62 SCH # 62 Perifosine 62 phase IIb 62 PRTX 62 INCB# [001] 62 AQ4N 62 Silodosin 62 Omacetaxine 62 subcutaneous formulation 62 teriflunomide 62 Panzem R 62 Initiate Phase 62 Kinase Inhibitor 62 Phase 2a trial 62 PNP inhibitor 62 Phase #b/#a clinical 62 ATL/TV# 62 Tezampanel 62 PEG IFN 62 CDK inhibitor 62 ritonavir boosted 62 OXi# 62 Kahalalide F 62 radiolabeled 62 Allovectin 7 62 obatoclax 62 pertuzumab 62 Tesetaxel 62 novel VDA molecule 62 XL# XL# XL# 62 immunomodulatory therapy 62 Elvitegravir 62 Orally administered 62 Liposomal 62 Carfilzomib 62 registrational trial 62 Onalta ™ 62 UPLYSO 62 non nucleoside 61 NGX# 61 tanespimycin 61 ceftazidime 61 vinca alkaloid 61 potent inhibitor 61 inhaled formulation 61 AEGR 61 imatinib Gleevec ® 61 Inhalation Powder 61 methylnaltrexone bromide 61 vidofludimus 61 Personalized Immunotherapy 61 Phase Ib clinical trials 61 Phase 1b clinical 61 Janus Kinase 61 docetaxel Taxotere ® 61 etanercept Enbrel 61 Hsp# Inhibitor 61 direct renin inhibitor 61 ospemifene 61 Zoraxel TM 61 TLR9 agonist 61 AKT inhibitor 61 erlotinib Tarceva ® 61 human rDNA origin 61 non nucleoside HCV 61 novel histone deacetylase 61 Soliris eculizumab 61 Alfacell proprietary ribonuclease 61 HCD# [002] 61 DermaVir Patch 61 multi kinase inhibitor 61 HCV polymerase 61 Bicifadine 61 mesylate 61 ongoing Phase 1b 61 administered subcutaneously 61 dyskinesia PD LID 61 stated Michelle Berrey 61 Phase 1a 61 investigational compound 61 Onalta 61 pafuramidine 61 Aurora Kinase 61 Aflibercept 61 Polymer Microspheres 61 Phenoptin 61 ACAPODENE TM 61 gemcitabine cisplatin 61 CYT# potent vascular disrupting 61 lomitapide 61 nitazoxanide 61 forodesine 61 Phase 2a 61 topically applied SEPA 61 Aclidinium 61 pradefovir 61 RenaZorb TM 61 ocular formulation 61 ART# 61 MF# [002] 61 KB# [002] 61 Nanobody ® 61 miconazole Lauriad ® 61 Bezielle 61 Blinatumomab 61 boosted protease inhibitor 61 inhalation aerosol 61 Phase 2a clinical 61 Delafloxacin 61 novel synthetic peptide 61 Hsp# inhibitor 61 Amplimexon 61 Methylnaltrexone 61 TNF Tumor Necrosis Factor 61 paclitaxel Taxol 61 selective estrogen receptor modulator 61 luliconazole 61 generation FBPase inhibitor 61 GLPG# 61 Phase 1b trial 61 XL# anticancer compounds 61 elotuzumab 61 INCB# [002] 61 multicenter Phase II 61 favorable pharmacokinetic profile 61 preclinically 61 oxazolidinone 61 eprotirome 61 highly selective inhibitor 61 topical ophthalmic 61 nucleotide analog 61 CRLX# 61 cetuximab Erbitux ® 61 cilengitide 61 DDP# 61 ALN PCS 61 CA4P 61 Traficet EN 61 seliciclib CYC# 61 ARC# [001] 61 Omacetaxine mepesuccinate 61 YONDELIS 61 AAG geldanamycin analog 61 Albuferon TM 61 Oral NKTR 61 rHuPH# recombinant human 61 oral antiviral 61 humanized antibody 61 thalidomide Thalomid 61 PrevOnco 61 CXA 61 tenofovir Viread 61 GLP toxicology studies 61 RH1 61 Imprime PGG 61 sunitinib Sutent ® 61 PEGylated Fab fragment 61 Panzem NCD 61 MKC# MKC# PP 61 Inhalation Solution 61 Inhalation Aerosol 61 inhibitor RG# 61 tivozanib 61 LymphoStat B TM 61 VEGF inhibitor 61 Zerenex 61 Radezolid 60 Microspheres 60 DAVANAT 60 CD# monoclonal antibody 60 plasma kallikrein inhibitor 60 humanized anti 60 generation Hsp# inhibitor 60 Besivance 60 Thiovir 60 Novolimus 60 Debio 60 Kamada AAT 60 Sphingomab 60 TriRima 60 Spiegelmer ® 60 investigational oral 60 hypoxia activated prodrug 60 DUROS 60 Sapacitabine 60 kinase inhibitor 60 trodusquemine 60 Aurora kinase inhibitor 60 subcutaneously administered 60 SLx 60 Phase 2b clinical 60 6R BH4 60 RGB # 60 Seliciclib 60 NEUGENE 60 investigational integrase inhibitor 60 DEB# 60 HDAC Inhibitor 60 VA# [002] 60 KRN# 60 Vidofludimus 60 Copegus ribavirin 60 phase IIb study 60 Enhanze Technology 60 Phase IIb clinical trials 60 IND enabling 60 XmAb# 60 HCV protease 60 Onconase 60 octreotide implant 60 Bortezomib 60 HuLuc# 60 intravenously administered 60 Cloretazine ® 60 long acting muscarinic 60 BRIM2 60 prodrug 60 signal transduction inhibitor 60 oral nucleoside analogue 60 small molecule Hedgehog 60 selectively inhibits 60 Phase 1a clinical 60 ADP receptor antagonist 60 echinocandin 60 Anticalin R 60 torezolid phosphate 60 PSMA ADC 60 PI3K/Akt pathway inhibitor 60 TLR8 agonist 60 Glucagon Like Peptide 60 Actilon 60 oral ridaforolimus 60 docetaxel Taxotere 60 initiated Phase Ib 60 nanoviricides 60 5 HT3 antagonist 60 DPP4 inhibitor 60 sorafenib Nexavar 60 ASONEP 60 hormone LHRH antagonist 60 topical gel formulation 60 selective agonist 60 Pharmacokinetics PK 60 IMiDs ® 60 HuMax 60 Serdaxin 60 subcutaneous SC 60 murine monoclonal antibody 60 Denufosol 60 iobenguane 60 COX Inhibiting Nitric Oxide 60 OMP #M# 60 Pramlintide 60 Talabostat 60 FK# 60 Fx #A 60 Interferon alpha 60 Peginterferon 60 novel orally administered 60 Apoptone 60 rxRNA 60 dihydrochloride 60 injected intramuscularly 60 thiazolidinedione TZD 60 Nexavar ® 60 Lixivaptan 60 amphotericin B 60 Chemophase 60 PRX# 60 radezolid 60 vascular disrupting agents 60 Phase 2a Clinical Trial 60 Glufosfamide 60 Solulin 60 nucleoside polymerase inhibitor 60 Azixa 60 Azedra TM 60 Aplidin R 60 regorafenib 60 HspE7 60 ATL# [001] 60 Parkinson disease levodopa induced 60 Luteinizing Hormone Releasing Hormone 60 cysteamine bitartrate 60 TBC# 60 injectable formulation 60 IAP inhibitors 60 angiotensin receptor blocker ARB 60 Varespladib 60 Crofelemer 60 dexpramipexole 60 quinoline 60 Anavex #-# 60 Meets Primary Endpoint 60 corticosteroid dexamethasone 60 isoform selective 60 #mg/#mg 60 Antigenics QS 60 SERMs 60 transcriptase inhibitor NNRTI 60 Alzhemed TM 60 VAPRISOL 60 Degarelix 60 torezolid 60 NP2 60 reversible inhibitor 60 mGluR5 negative 60 Recombinant Human 60 AERx iDMS 60 aurora kinase 60 Vaxfectin 60 Eltrombopag 60 triphendiol 60 glucokinase activator 60 phase IIb trial 60 retapamulin 60 TRIOLEX 60 Vidaza azacitidine 60 LB# [003] 60 SGLT2 inhibitor 60 intravesical instillation 60 PHX# 60 TELCYTA 60 TPI ASM8 60 bevacizumab Avastin 60 renin inhibitors 60 novel oral anticoagulant 60 luteinizing hormone releasing 60 PI3K/mTOR 60 pharmacokinetics PK 60 IRX 2 60 MKC# 60 albiglutide 60 Phase 1b 60 nanomolar range 60 Phase Ib 60 radiolabeled monoclonal antibody 60 EOquin TM 60 JAK1 60 chemokine receptor 60 ZK EPO 60 Bremelanotide 60 PEG Interferon lambda 60 CG# [001] 59 NXL# 59 Zybrestat 59 XL# XL# XL# XL# 59 Teysuno 59 pharmacodynamic properties 59 Randomized Phase 59 REG2 59 beta 1a 59 Phase IIb Trial 59 PKC# 59 KSP inhibitor 59 Ceflatonin 59 elvitegravir 59 EP# [003] 59 pegfilgrastim 59 OMNARIS Nasal Spray 59 rHuPH# 59 biologic DMARD 59 uricase 59 CBLC# 59 Nanobody 59 dasatinib Sprycel 59 orally inhaled 59 Formoterol 59 orally administered 59 RDEA# 59 CG# [003] 59 HCV protease inhibitors 59 antisense oligonucleotide 59 Romidepsin 59 oral Hsp# inhibitor 59 ISENTRESS raltegravir 59 iSONEP 59 hyaluronidase enzyme 59 Darinaparsin 59 Pemetrexed 59 Phase 2b Clinical Trial 59 cathepsin K inhibitor 59 potently inhibit 59 Menerba 59 Anticalin 59 Aviptadil 59 developing Bicifadine serotonin 59 tipifarnib 59 Hsp# inhibitors 59 Azedra ™ 59 CCR9 antagonist 59 Naproxcinod 59 Leukine ® 59 sodium glucose transporter 59 talabostat 59 Linaclotide 59 Phase IIa clinical 59 Muraglitazar 59 subcutaneously injected 59 vapreotide acetate 59 PNT# 59 Sustiva efavirenz 59 lamivudine zidovudine 59 amrubicin 59 oral proteasome inhibitor 59 THR beta agonist 59 Kevetrin 59 GALNS 59 Junovan TM 59 Pathway Inhibitor 59 PDX pralatrexate 59 peritumoral brain edema 59 adenosine A2A 59 NU# [001] 59 Aplidin 59 FVIIa 59 tumor xenograft models 59 anti CD3 59 Immunotherapeutic 59 BrachySil 59 crofelemer 59 nitric oxide donating prostaglandin 59 oxidative stress inducer 59 2 inhibitor CYT# 59 sodium thiosulfate STS 59 investigational protease inhibitor 59 oral formulation 59 Zerenex ™ 59 DNA intercalator 59 peripherally acting 59 pharmacokinetic PK study 59 Aurexis 59 BrachySil ™ 59 VivaGel TM 59 AZX# 59 sublingual formulation 59 selective modulator 59 Cannabinor 59 indibulin 59 Ixabepilone 59 immunotherapeutic vaccine 59 ZYVOX 59 Clolar ® 59 Cleviprex TM clevidipine 59 Zolinza 59 Iluvien TM 59 humanised antibody 59 maximally tolerated dose 59 cetuximab Erbitux R 59 IMiDs R 59 topical gel containing 59 HEPLISAV TM 59 ARIKACE ™ 59 ORENCIA ® 59 Epanova 59 pegylated interferon alpha 59 Investigational Oral 59 Troxatyl 59 AIR# [001] 59 eniluracil 59 Aganocide ® 59 CR# vcMMAE 59 fludarabine phosphate 59 OncoVEX 59 protease inhibitor PI 59 novel prodrug 59 Melphalan 59 xanthine oxidase inhibitor 59 MAP# 59 pegylated interferons 59 ALS #-# 59 refractory gout 59 Laquinimod 59 Zysolin TM 59 Pazopanib 59 Phase Ib II 59 INC# 59 Resten NG 59 otelixizumab 59 LEP ETU 59 BRAF inhibitor 59 ulimorelin 59 LHRH antagonist 59 lapatinib Tykerb 59 metformin sulfonylurea 59 NVA# 59 Interferon alfa 59 cannabinor 59 MTP inhibitor 59 Syncria 59 Tanespimycin 59 Bavituximab 59 liposomal doxorubicin 59 Phase 1b clinical trials 59 TKM ApoB 59 bevacizumab Avastin ® 59 Argatroban 59 Glatiramer Acetate 59 combretastatin A4 phosphate CA4P 59 polymerase inhibitors 59 nucleotide analogue 59 GTC recombinant human 59 ChronVac C R 59 Phase III Clinical Trial 59 daptomycin 59 tezampanel 59 huN# DM1 59 CRMD# 59 PrevOnco ™ 59 Phase 2a clinical trials 59 pomalidomide 59 Panzem 59 Cloretazine 59 AMPA kainate 59 nucleoside analogue 59 cidofovir 59 outlicensed 59 humanized monoclonal 59 aleglitazar 59 EZN 59 selective A2A adenosine receptor 59 recombinant adeno associated 59 acetonide FA 59 ritonavir boosted protease inhibitor 59 Dalbavancin 59 melphalan prednisone 59 SRT# [003] 59 Capesaris 59 Entecavir 59 Zorbtive TM 59 selective phosphodiesterase 59 brivaracetam 59 receptor modulators 59 KB# [004] 59 RELOVAIR ™ 59 Cethrin R 59 trabectedin 59 Phase IIIb clinical 59 Voreloxin 59 selective immunoproteasome inhibitor 59 JZP 59 Thiarabine 59 atacicept 59 Vivecon 59 SPC# [001] 59 Xeloda ® 59 Prodarsan ® 59 Tarmogen 59 Hycamtin 59 HYLENEX recombinant 59 aldehyde dehydrogenase ALDH2 deficiency 59 CCR2 59 Angiocept 59 Aptivus ® 59 Aerosurf 59 essential thrombocythemia ET 59 cleavable linker 59 anti infective treatments 59 telaprevir VX 59 RenaZorb 59 epothilone 59 Plicera 59 tiapamil 59 VRX# [002] 59 MYDICAR ® 59 Tarceva TM 59 lucinactant 59 NRTI resistance 59 HDACi 59 CB2 selective receptor agonist 59 Rosuvastatin 59 BLyS specific 59 Initiated Phase 59 EDEMA3 59 delivers fluocinolone acetonide FA 59 bevacizumab Avastin R 59 recombinant subunit vaccine 59 dose escalation Phase 59 fluoroquinolone antibiotic 59 Saxagliptin 59 Janus kinase 59 sulodexide 59 dose escalation trial 59 IND submission 59 XYOTAX TM 59 TKB# 59 Belimumab 59 PEGylated anti 59 Ambrisentan 59 Granisetron 59 Tamibarotene 59 investigational drug 59 inhalation powder 59 PG# [004] 59 vivo validation 59 RAPAFLO 59 entinostat 58 Cysteamine 58 APEX PD 58 selective inhibitor 58 BYETTA ® 58 S/GSK# 58 denileukin diftitox 58 IL# PE#QQR 58 TAFA# 58 DXL# 58 Alinia 58 antiangiogenic agent 58 perifosine 58 nilotinib Tasigna ® 58 #D#C# 58 IAP inhibitor 58 cholesteryl ester transfer 58 Cyclosert 58 CIMZIA TM 58 ABL inhibitor 58 Aztreonam 58 Phase IIb trials 58 Gemzar ® 58 Elesclomol 58 Aeroquin 58 Evoltra ® 58 EndoTAG TM -1 58 L BLP# 58 oral dual endothelin 58 HuMax TAC 58 Alferon N 58 DCCR 58 drug GLPG# 58 protease inhibitor 58 deforolimus 58 Amigal 58 AVP #D# 58 Deforolimus 58 BCR ABL inhibitors 58 oral renin inhibitor 58 delafloxacin 58 Epratuzumab 58 Q#IR 58 allosteric modulator NAM 58 Completes Patient Enrollment 58 Rigel R# 58 Dacogen decitabine 58 HCV replicon 58 product candidate Lpathomab 58 APTIVUS 58 Spiegelmer 58 Ozarelix 58 Myocet 58 Prodrug 58 GRNVAC1 58 small molecule tyrosine 58 oral salmon calcitonin 58 neratinib 58 topically administered 58 CINOD 58 MVA BN R 58 Diabetic Macular Edema DME 58 plerixafor 58 panitumumab Vectibix 58 HepaSphere 58 inhibitor PPI 58 NPC 1C 58 Dabigatran etexilate 58 temsirolimus Torisel ® 58 lexidronam injection 58 VQD 58 Ceflatonin R 58 Fc fusion protein 58 Anticalin ® 58 PARP inhibitor 58 IMPDH inhibitor 58 XP# XP# 58 HDAC inhibitor 58 TELINTRA 58 darinaparsin ZIO 58 IDX# 58 oncolytic virus 58 AFREZZA TM 58 Phase IIb clinical 58 OXIGON TM 58 PLK1 SNALP 58 MB# MB# 58 Indaflex TM 58 5 HT2A inverse 58 Lenocta TM 58 Zoraxel 58 Atripla combines 58 Atrasentan 58 FluCide 58 histone deacetylase HDAC inhibitors 58 VELCADE melphalan 58 PEGPH# 58 anti CD3 monoclonal 58 Squalamine 58 Fenretinide 58 immunomodulatory 58 ketolide antibiotic 58 plus DOXIL 58 KN# [001] 58 EKC Cide 58 highly selective endothelin 58 Initiates Clinical 58 Ecallantide 58 AP# [003] 58 calcitonin 58 RNAi therapeutic targeting 58 candidate deforolimus 58 dacetuzumab 58 Medidur TM FA 58 epigenetic therapies 58 diclofenac sodium 58 metastatic malignant 58 NM# [003] 58 CTA# 58 PSN# [001] 58 defensin mimetic antibiotic 58 metformin hydrochloride 58 BENLYSTA ® 58 favorable tolerability 58 assessing T DM1 58 OHR/AVR# 58 #I TM# 58 Cloretazine R VNP#M 58 Ophena TM 58 siRNA therapeutic 58 GLP1 INT TM 58 tolevamer 58 Anidulafungin 58 diarrhea predominant irritable 58 Ampligen ® 58 HepDirect prodrug 58 OXIGON 58 Telmisartan 58 Deadlinepix 58 trastuzumab DM1 T DM1 58 SUTENT ® 58 HGS ETR1 58 Maraviroc 58 phase IIa 58 Tasimelteon 58 immune stimulatory 58 bardoxolone 58 Cethromycin 58 tenofovir disoproxil fumarate Viread 58 EGS# 58 ThermoDox R 58 Drug Candidate 58 Pivotal Phase III 58 Pertuzumab 58 Rebif ® 58 VaxImmune 58 Intravesical 58 fluticasone furoate 58 Alocrest 58 Receptor Agonist 58 lamivudine 3TC 58 Moxifloxacin 58 retaspimycin hydrochloride 58 adenoviral vectors 58 Octreotide 58 antibody fragment 58 LymphoStat B belimumab 58 Technosphere Insulin 58 mecamylamine 58 Azacitidine 58 Vicriviroc 58 Shigamabs R 58 MNTX 58 Gleevec resistant 58 PEGylated 58 neuroprotective properties 58 anti amnesic 58 Zemiva ™ 58 diabetic neuropathic pain 58 betrixaban 58 Vilazodone 58 AzaSite Plus 58 docetaxel chemotherapy 58 acyclovir Lauriad R 58 cyclin dependent kinase inhibitor 58 Etravirine 58 DU #b 58 Phase 2b trial 58 sargramostim 58 tenofovir emtricitabine 58 JAK3 inhibitor 58 Anticalins ® 58 Phase IIa trial 58 Phase 2b Trial 58 PGL# 58 overactive bladder AA# 58 bortezomib Velcade 58 REG1 58 potent topoisomerase II 58 cutaneous T 58 peptidomimetic 58 CTAP# Capsules 58 Symadex 58 novel anticancer 58 Topotecan 58 synthetic peptide 58 PORxin TM 58 gallium containing 58 Familial Adenomatous Polyposis FAP 58 NeuroSTAT ® 58 eltrombopag 58 Afatinib 58 pharmacokinetic profile 58 resolvin 58 Neulasta ® 58 Neo Urinary Conduit 58 GSK '# 58 systemic RNAi therapeutic 58 acadesine 58 Vaprisol 58 LAS# [002] 58 brivanib 58 R roscovitine 58 SPL# Gel vaginal microbicide 58 Pancreate 58 Phase Ia